Yadda AstraZeneca Ke Aiki

Yadda Astrazeneca ke aiki

Kamfanin magunguna AstraZeneca jagora ne a masana'antar kiwon lafiya kuma mai sadaukarwa ga bincike, haɓakawa da samar da magunguna. An kafa shi a cikin Burtaniya, wannan kamfani ya kasance majagaba a cikin haɓaka sabbin jiyya a fannoni daban-daban na likitanci, kamar ilimin cututtukan daji, cututtukan zuciya da na numfashi. A cikin wannan labarin, za mu bincika yadda ⁢ Astrazeneca ke aiki da kuma mayar da hankali kan gano hanyoyin kwantar da hankali da ke inganta rayuwar miliyoyin mutane a duniya.

Bincike da Ci gaba

Ɗaya daga cikin mahimman ginshiƙai na Astrazeneca shine sadaukarwa ga bincike da ci gaba na sababbin kwayoyi. Kamfanin yana ɗaukar ɗimbin ƙwararrun masana kimiyya da masu bincike, waɗanda ke aiki tare don ganowa da haɓaka sabbin hanyoyin kwantar da hankali. Ta hanyar gano maƙasudin warkewa, tabbatar da ƙwayoyin ƙwayoyin cuta da bincike na asibiti, Astrazeneca ya ci gaba da yin aiki tuƙuru don nemo mafita ga mafi ƙalubalanci cututtuka.

Hadin gwiwa da Kawance

Baya ga mayar da hankali na ciki akan bincike, Astrazeneca kuma ya kafa haɗin gwiwa da haɗin gwiwa tare da sauran kungiyoyi da kamfanoni a fannin. Wadannan dabarun haɗin gwiwar suna ba wa kamfanin damar yin amfani da ilimi da albarkatun abokan hulɗa na waje don ci gaba da bincike da ci gaba. Ta hanyar waɗannan haɗin gwiwar, Astrazeneca yana kulawa don haɓaka tsarin ci gaban miyagun ƙwayoyi kuma ya kawo "sababbin jiyya" zuwa kasuwa yadda ya kamata.

Production da Rarraba

Da zarar an haɓaka magungunan Astrazeneca kuma an yarda da su, suna fuskantar tsauraran tsarin gwaji. samarwa da rarrabawa. Kamfanin yana da manyan wurare da fasahohin da ke ba da garantin kera magunguna masu inganci da aminci. Babban hanyar rarraba ta, wanda ke goyan bayan tsauraran matakan sarrafawa da ayyuka masu kyau, yana ba da damar jiyya na Astrazeneca don isa ga marasa lafiya a duniya, yana ba su damar yin amfani da hanyoyin kwantar da hankali wanda zai iya yin tasiri mai mahimmanci ga lafiyar su.

A taƙaice, Astrazeneca sanannen kamfanin harhada magunguna ne na duniya wanda ke mai da hankali kan bincike, haɓakawa, samarwa da rarraba sabbin jiyya. Tare da mai da hankali kan haɗin gwiwa da binciken kimiyya, wannan kamfani yana ci gaba da inganta rayuwar miliyoyin mutane a duniya ta hanyar samar da ingantattun hanyoyin kwantar da hankali ga cututtuka masu yawa.

Yadda maganin Astrazeneca ke aiki

Antibodies da ƙwayoyin cuta: Lorem ipsum ‌dolor sit amet, consectetur adipiscing ‌elit. AstraZeneca yana amfani da hanyar da ta dogara da kwayar cutar hoto don haɓaka rigakafinta yana amfani da ƙwayar cuta mara lahani, chimpanzee adenovirus, azaman vector don isar da furotin na hoto na SARS-CoV-2 a cikin jiki. Wannan furotin na hoto iri ɗaya ne da ake samu a saman ƙwayoyin cuta kuma ana kiransa da S ko sunadaran spike.

Amsar rigakafi: Da zarar kwayar halittar chimpanzee adenovirus ta shiga cikin sel na jikin ɗan adam, Umurnin kwayoyin halitta na kwayar cutar yana haifar da sel don samar da furotin S na SARS-CoV-2. Wadannan sunadaran suna bayyana a saman sel kuma suna faɗakar da tsarin rigakafi na yiwuwar kamuwa da cutar hoto. Sa'an nan tsarin rigakafi yana kunna amsawar rigakafi, yana samar da takamaiman ƙwayoyin rigakafi akan furotin S.

Kariya daga kamuwa da cuta: Da zarar an samar da maganin rigakafi, jiki yana shirye don kare kansa idan ya ci karo da ainihin kwayar cutar. Idan mutumin da aka yi wa alurar riga kafi da AstraZeneca ya zo cikin hulɗa da SARS-CoV-2, ƙwayoyin rigakafin da aka samar don mayar da martani ga furotin S za su ɗaure kwayar cutar kuma su kawar da ita, don haka suna hana kwayar cutar kamuwa da kwayar cutar ta COVID-19. Bugu da ƙari, ƙwayoyin rigakafi, rigakafin kuma yana ƙarfafa martanin ƙwayoyin T, waɗanda za su iya gano da lalata ƙwayoyin da ke kamuwa da kwayar cutar.

Bayanan asali game da rigakafin Astrazeneca

Maganin rigakafin Astrazeneca, wanda aka haɓaka tare da haɗin gwiwar Jami'ar Oxford, ya dogara ne akan tsarin da aka saba amfani da shi wajen samar da rigakafin. Yana amfani da kwayar cutar chimpanzee da aka gyara Wanda ke ɗauke da nau'in kwayar cutar SARS-CoV-2 mara lahani, kwayar cutar da ke haifar da cutar COVID-19. -CoV virus 2 a cikin jikin mutum ba tare da haifar da cuta ba. Ta hanyar gabatar da wannan furotin ga tsarin rigakafi, ana haifar da amsa wanda ke haifar da ƙwayoyin rigakafi da ƙwayoyin rigakafi don kare jiki daga cutar.

Da zarar an gudanar da shi, maganin Astrazeneca yana taimakawa wajen horar da tsarin rigakafi Don gane da yaƙi da kwayar cutar SARS-CoV-2. Wannan na iya rage haɗarin haɓaka mai tsanani COVID-19 ko rikice-rikice masu alaƙa. Nazarin asibiti ya nuna cewa maganin Astrazeneca yana da matukar tasiri wajen hana rashin lafiya mai tsanani da kuma asibiti sakamakon COVID-19. Bugu da kari, yana da mahimmanci a nuna cewa hukumomin da suka dace sun amince da shi kuma an nuna cewa yana da aminci don karewa daga cutar COVID-19.

Yana da mahimmanci a san wasu illolin gama gari waɗanda ke da alaƙa da rigakafin Astrazeneca. Wadannan illolin gabaɗaya suna da sauƙi kuma suna ɓacewa cikin ƴan kwanaki.Suna iya haɗawa da ciwo ko taushi a wurin allurar, gajiya, zazzabi, ciwon kai, da ciwon tsoka. Wadannan alamun alamun suna nuna cewa tsarin rigakafi yana amsa maganin alurar riga kafi kuma yana haɓaka kariya daga cutar.

Abubuwan da ke cikin maganin Astrazeneca da tasirin sa akan jiki

Alurar rigakafin Astrazeneca ta ƙunshi nau'ikan abubuwa masu mahimmanci waɗanda ke taka muhimmiyar rawa a cikin aikinta da tasirin sa akan jiki. Daya daga cikin manyan abubuwan da aka gyara shine Chimpanzee adenovirus ⁢virus (ChAdOx1), wanda aka gyara ta hanyar kwayoyin halitta don ɗaukar ƙwayar furotin mai karu daga kwayar cutar SARS-CoV-2. Wannan furotin shine mabuɗin ta yadda kwayar cutar za ta iya shiga cikin ƙwayoyin ɗan adam kuma ta yi kwafi.

Wani bangaren shine karu sunadaran na kwayar cutar SARS-CoV-2 da kanta, wacce ke samuwa a cikin nau'in da ba a kunna ba a cikin maganin rigakafi An gane wannan furotin a matsayin barazana kuma yana haifar da samar da kwayoyin cuta. Ta hanyar shigar da wannan furotin da ba a kunna ba a cikin jiki, maganin yana ƙarfafa amsawar rigakafi, ⁢ yana taimakawa wajen shirya tsarin garkuwar jiki a yanayin bayyanar cutar ta ainihi a nan gaba.

Baya ga abubuwan da ke sama, rigakafin kuma ya ƙunshi adjuvants, waxanda suke da abubuwan da ke inganta amsawar rigakafi. Ana amfani da waɗannan adjuvants don haɓaka martanin tsarin rigakafi ga furotin mai karu da haɓaka tasirin maganin Astrazeneca, adjuvant ɗin da aka yi amfani da shi shine MF59, wanda aka nuna yana da aminci da tasiri a cikin sauran rigakafin.

Ingantaccen rigakafin Astrazeneca da bayanan asibiti

HANKALI NA AIKI

Alurar rigakafin Astrazeneca tana amfani da fasaha bisa ga a wanda ba mai yin kwafi baA wannan yanayin, adenovirus chimpanzee da aka canza ta kwayoyin halitta, wanda ke dauke da wani bangare na kwayoyin halittar kwayar cutar SARS-CoV-2. Da zarar an gudanar da shi, adenovirus yana shiga cikin sel na jiki, inda yake fitar da bayanan kwayoyin halittar kwayar cutar ta COVID-19, yana haifar da amsawar rigakafi. Wannan yana haifar da samar da antibodies da kwayoyin T ƙwararre, mai iya ganewa da kuma kawar da kwayar cutar ta ainihi a cikin yanayin kamuwa da cuta a nan gaba.

INGANTATTU DA TSIRA

An gwada tasirin maganin Astrazeneca a cikin manyan gwaje-gwaje na asibiti da yawa, waɗanda suka nuna inganci 79% don hana alamun bayyanar cututtuka na COVID-19. Bugu da ƙari, raguwa mai mahimmanci a cikin ⁢ tsananin cutar a cikin wadanda suka kamu da cutar. Game da aminci, an gudanar da cikakken bincike wanda ya tabbatar da ingantaccen bayanin amfanin amfanin sa. Duk da cewa ba kasafai aka ba da rahoton bullar cutar sankarau ba, an kammala cewa fa'idodin rigakafin sun zarce haɗarin da ke tattare da su, musamman idan aka yi la'akari da mummunan tasirin cutar ta COVID-19.

BANBANCI DELTA DA SHAWARAR KASHI

An gano cewa maganin Astrazeneca kuma yana da tasiri a kan variante Delta na kwayar cutar, wanda ya nuna mafi girman iya yaduwa idan aka kwatanta da bambance-bambancen da suka gabata. Don samun mafi kyawun kariya, ana ba da shawarar karɓar allurai biyu na alluran rigakafin bisa ga tsarin da aka kafa, mutunta tazara mai dacewa. Yana da mahimmanci a nuna cewa duka kashi na farko da na biyu suna da mahimmanci don cimma iyakar tasirin maganin da kuma tsawaita kariya daga cutar.

Mafi yawan halayen rashin lafiya na yau da kullun masu alaƙa da maganin Astrazeneca

Alurar rigakafin Astrazeneca ya tabbatar da kasancewa muhimmiyar ci gaba a cikin yaƙi da COVID-19, amma kamar kowane magani, akwai yuwuwar. reacciones adversas cewa dole ne a yi la'akari. Ko da yake mafi yawan mutanen da aka yi wa allurar ba sa fuskantar mummunar illa, yana da mahimmanci a sanar da su game da mafi yawan waɗanda ke da alaƙa da wannan maganin.

Daga cikin mafi na kowa m halayen An ba da rahoton bayan gudanar da allurar rigakafin Astrazeneca:

• Ciwo ko kumburi a wurin allurar.
• Jin rashin jin daɗi na gaba ɗaya.
• Matsakaicin zazzabi.
• Dolor de cabeza.
• Fatiga.

Yana da mahimmanci a lura cewa waɗannan alamun yawanci suna da sauƙi ko matsakaici kuma suna ɓacewa cikin ƴan kwanaki amma, idan kun sami wani sakamako mai tsayi ko mai tsanani, yana da kyau a nemi kulawar likita nan da nan.

Yana da mahimmanci a ambaci cewa idan kun sami rashin lafiyar jiki mai tsanani zuwa wani ɓangaren da ya gabata na maganin Astrazeneca, kamar polyethylene glycol, ƙila ba za ku iya samun wannan maganin ba. ⁢ Bugu da kari, yana da mahimmanci ka yi magana da likitanka kafin a yi alurar riga kafi idan kana da wasu yanayin kiwon lafiya, kamar raunin tsarin garkuwar jiki ko kuma tarihin rashin lafiyar jini. Gabaɗaya, an nuna maganin Astrazeneca yana da aminci da tasiri wajen hana COVID-19, amma yana da mahimmanci a kimanta haɗarin mutum da fa'idodin kafin yanke shawara game da rigakafin.

Shawarwari don gudanarwa da adana maganin AstraZeneca

Yana da mahimmanci a bi wasu shawarwari don tabbatar da ingantaccen gudanarwa da adana maganin AstraZeneca. Da farko, yana da mahimmanci don girmama sarkar sanyi. Ya kamata a adana maganin a zafin jiki tsakanin 2 ° C zuwa 8 ° C, don guje wa sauye-sauyen da zai iya lalata tasirinsa. Bugu da ƙari, lokacin gudanar da shi, wajibi ne a yi amfani da allura da sirinji masu amfani da bakararre, don haka tabbatar da amincin tsarin.

Hakazalika, ana ba da shawarar kula sosai kan jadawalin allurar da hukumomin lafiya suka kafa. Ana yin allurar rigakafin Astrazeneca a cikin allurai biyu, an raba ta tazara na kusan makonni 12. Yana da mahimmanci a mutunta wannan lokacin don tabbatar da iyakar kariya daga cutar. Bayan haka, Yana da mahimmanci a gano da kyau da kuma yin rijistar marasa lafiya waɗanda suka karɓi maganin, don sauƙaƙe sanarwar yiwuwar illa da kuma lura da martanin rigakafin su..

Wani muhimmin shawara shine a hankali kula da ranar karewa na maganin Astrazeneca. Kafin gudanar da shi, dole ne a tabbatar da cewa samfurin yana cikin ranar karewa. In ba haka ba, bai kamata a yi amfani da shi ba, saboda tasirinsa na iya lalacewa. Bugu da kari, dole ne a adana maganin a cikin marufinsa na asali, tare da kare shi daga hasken kai tsaye da kuma kiyaye shi daga isar mutanen da ba su da izini don tabbatar da kulawa da kyau da kuma adana shi yana da mahimmanci don kiyaye ingancinsa da ingancinsa .

Tunani game da maganin AstraZeneca da amfani da shi a cikin ƙungiyoyin jama'a daban-daban

Alurar rigakafin Astrazeneca ta tabbatar da yin tasiri wajen karewa daga ƙwayar cuta ta COVID-19 kuma an ba da izinin amfani da ita a cikin ƙungiyoyin jama'a daban-daban. Duk da haka, yana da mahimmanci a yi la'akari da wasu la'akari kafin gudanar da wannan maganin ga wasu mutane.

Da fari dai, an lura cewa tasirin maganin Astrazeneca na iya bambanta dangane da shekarun mutum. Nazarin ya nuna cewa tasirin rigakafin ya fi girma a cikin matasa da masu matsakaicin shekaru, yayin da zai iya yin ƙasa a cikin tsofaffi. Don haka, yana iya zama dole a yi la'akari da wasu zaɓuɓɓukan rigakafin a cikin mutanen da suka tsufa ko kuma suna da yanayin rashin lafiya.

Bugu da ƙari, an ba da rahoton lokuta masu wuya na abubuwan thromboembolic a cikin mutanen da suka karɓi maganin Astrazeneca. Wadannan lokuta ba su da yawa, amma yana da mahimmanci a yi la'akari da yiwuwar haɗari kafin ba da wannan maganin, musamman ma a cikin mutanen da ke da haɗari na toshewar jini. Ana ba da shawarar yin shawarwari tare da ƙwararren kiwon lafiya don kimanta haɗarin mutum da fa'idodi a kowane hali.

Yiwuwar hulɗar miyagun ƙwayoyi da contraindications na maganin Astrazeneca

Hulɗar Magunguna: Yana da mahimmanci a lura cewa maganin Astrazeneca na iya yin hulɗa tare da wasu magunguna, don haka yana da mahimmanci don sanar da likitan ku game da duk wani magani da kuke karɓa. Wasu magungunan da za su iya yin hulɗa tare da maganin sun haɗa da magungunan rigakafi, magungunan anti-inflammatory marasa steroidal (NSAIDs), da kuma corticosteroids.

Contraindicaciones: An hana rigakafin AstraZeneca a wasu takamaiman yanayi. Mutanen da suka fuskanci wani mummunan rashin lafiyar maganin alurar riga kafi a wani kashi na baya ko ga kowane ɓangaren maganin ya kamata su guje wa ƙarin gudanarwa. Bugu da ƙari, waɗanda ke da tarihin coagulopathy ko cututtukan jini, irin su thrombocytopenia, yakamata su tuntuɓi likitan su kafin. karɓi allurar rigakafin. Yana da mahimmanci don sanin waɗannan contraindications kuma bi shawarwarin masana likita.

Matakan kariya: Kodayake maganin Astrazeneca gabaɗaya yana da aminci kuma yana da tasiri, yakamata a yi amfani da hankali a wasu rukunin marasa lafiya. Waɗanda ke da cututtuka na autoimmune, cututtuka na tsarin rigakafi, ciki ko shayarwa ya kamata su tuntuɓi likitan su kafin su karbi maganin. Bugu da ƙari, ya kamata a yi amfani da hankali ga mutanen da ke da tarihin ciwon jini ko kuma waɗanda ke shan magungunan da ke damun jini. Yana da kyau koyaushe a yi magana da ƙwararren kiwon lafiya don karɓar keɓaɓɓen jagora game da allurar rigakafi tare da Astrazeneca.

Bincike da sabuntawa akan maganin Astrazeneca

Yadda Astrazeneca ke aiki:

Alurar rigakafin Astrazeneca, wanda kuma aka sani da Vaxzevria, wani maganin ƙwayar cuta ne da ake amfani da shi don hana kamuwa da cutar ta SARS-CoV-2, dalilin COVID-19 Karu na furotin na ƙwayoyin cuta. Lokacin da ake gudanar da shi, adenovirus yana gabatar da kwayoyin halitta a cikin sel, yana haifar da samar da furotin mai karu. Ana gane wannan furotin ta tsarin garkuwar jiki, yana samar da martanin kariya daga kamuwa da cutar nan gaba. Yana da mahimmanci a lura cewa maganin yana buƙatar allurai biyu don samun ingantaccen rigakafi.

Tasirin maganin Astrazeneca ya kasance batun bincike da sabuntawa. Bisa ga binciken asibiti da aka gudanar, Alurar riga kafi ya nuna inganci wajen hana cututtukan da ke nuna alamun kusan kashi 80% ⁤ kuma an nuna cewa yana da matukar tasiri wajen hana cututtuka masu tsanani da kuma asibiti. Bugu da ƙari, an gano maganin yana da kyakkyawan bayanin tsaro, tare da mafi yawan illolin kasancewa masu sauƙi ko matsakaici.

Ko da yake an ba da rahoton lokuta masu wuya na thrombosis tare da thrombocytopenia bayan gudanar da maganin rigakafin AstraZeneca, an kammala cewa amfanin ya zarce kasada a yawancin al'umma. A matsayin yin taka tsantsan, ƙasashe da yawa sun kafa ƙayyadaddun amfani da su bisa dalilai na alƙaluma, kamar shekaru, don rage haɗarin haɗari. Koyaya, Hukumar Lafiya ta Duniya da Hukumar Kula da Magunguna ta Turai sun bayyana cewa fa'idodin allurar AstraZeneca gabaɗaya sun fi haɗari kuma ya kamata a ci gaba da amfani da shi a cikin shirye-shiryen rigakafin. Yana da mahimmanci mutane su tuntuɓi likitansu ko hukumomin kiwon lafiya na gida don ƙarin bayani game da allurar rigakafi tare da Astrazeneca.

Hanyoyi na gaba da ci gaba da kimanta rigakafin Astrazeneca

Yadda Astrazeneca ke aiki:

Maganin rigakafin Astrazeneca, wanda aka haɓaka tare da haɗin gwiwar Jami'ar Oxford, ya tabbatar da yin tasiri wajen hana COVID-19 kuma ya taka muhimmiyar rawa wajen yaƙar cutar. Koyaya, kamar yadda yake tare da kowane allurar rigakafi, amincinsa da ingancinsa suna ƙarƙashin ƙima mai gudana. Kamar yadda ake gudanar da shi a duk faɗin duniya, masana suna ci gaba da sanya ido kan bayanan tare da kimanta tasirin sa a cikin mutane daban-daban da bambance-bambancen cutar.

An kimanta tasirin maganin Astrazeneca a cikin tsauraran gwaji na asibiti wanda ya haɗa da dubban mahalarta. Sakamakon waɗannan gwaje-gwajen ya nuna cewa rigakafin yana da matukar tasiri wajen hana mummunan lamuran COVID-19, asibiti da mutuwa. Bugu da ƙari, ƙarin bincike ya nuna cewa maganin yana da tasiri a kan bambance-bambancen ƙwayoyin cuta, wanda ke da mahimmanci don yaƙar ci gaba da ci gaba na ƙwayar cuta.

Don tabbatar da amincin maganin, ana ci gaba da sa ido kan illolin da ke faruwa. Bayanan da aka tattara daga miliyoyin mutanen da aka yi wa alurar riga kafi ana kuma bincikar su akai-akai don gano yiwuwar illolin da ba kasafai ba. Yayin da aka ba da rahoton wasu lokuta na zubar da jini a matsayin sakamako masu illa, yana da mahimmanci a lura cewa waɗannan lokuta suna da wuyar gaske kuma ana yin bincike sosai don fahimtar ƙungiyar da kuma kimanta yiwuwar haɗari.